参考文献/References:
[1] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359: 378 - 390.
[2] Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma[J]. Semin Liver Dis, 2007, 27: 55 - 76.
[3] Beeram M, Patnaik A, Rowinsky EK. Regulation of c-Raf-1: therapeutic implications[J]. Clin Adv Hematol Oncol, 2003, 1: 476 - 481.
[4] Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma[J]. Gut, 2003, 52: 706 - 712.
[5] Hwang YH, Choi JY, Kim S, et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma[J]. Hepatol Res, 2004, 29: 113 - 121.
[6] Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res, 2004, 64: 7099 - 7109.
[7] Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models[J]. Cancer Chemother Pharmacol, 2007, 59: 561 - 574.
[8] Cheng AL, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-biind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10: 25 - 34.
[9] Lian M, Liu Y, Yu SZ, et al. Hepatitis B virus x gene and cyanobacterial toxins promote aflatoxin B1-induced hepatotumor-igenesis in mice[J]. World J Gastroenterol, 2006, 12: 3065 - 3072.
[10] Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66: 11851 - 11858.
[11] Lee S, Yoon S, Kim DH. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian Cancer cells[J]. Gynecol Oncol, 2007, 104: 338 - 344.
[12] Katayama K, Yoshioka S, Tsukahara S, et al. Inhibition of the mitogen-activated protein kinase pathway results in the down-regnlation of P-glycoprotein[J]. Mol Cancer Ther, 2007, 6: 2092 - 2102.
[13] 丁晓蕾, 张 阳, 吴 涛. 索拉非尼逆转肝癌细胞株HepG2/GEM耐药作用的实验研究[J]. 中华肿瘤防治杂志, 2010, 17: 1160 - 1163.
[14] 闫 东, 刘德忠, 曾辉英, 等. TACE联合索拉非尼治疗肝细胞癌的临床观察[J]. 临床肿瘤学杂志, 2010, 15: 359 - 361.
[15] 黄 振, 毕新宇, 赵建军, 等. 索拉非尼联合经导管肝动脉化疗栓塞治疗无远处转移的晚期肝细胞癌[J]. 临床肿瘤学杂志, 2010, 15: 355 - 358.
相似文献/References:
[1]曹海利,孟巍,白彬.肝癌基因治疗研究新进展[J].介入放射学杂志,2008,(05):375.
CAO Haili,MENG Wei,BAI Bin.New progress in research of gene therapy for hepatocellular carcinoma[J].journal interventional radiology,2008,(10):375.
[2]陆骊工,胡宝山,李勇,等.中晚期原发性肝癌合并症的介入治疗研究[J].介入放射学杂志,2008,(07):514.
LU Ligong,HU Baoshan,LI Yong,et al.Study of interventional therapy for complications in advanced primary hepatocellular carcinoma[J].journal interventional radiology,2008,(10):514.
[3]杨伟洪,刘鹏程,梁珊瑚,等.多层螺旋CT血管造影在判断肝癌寄生供血中的价值[J].介入放射学杂志,2008,(09):654.
YANG Weihong,LIU Pengchen g,LIANG Shanhu,et al.Evaluation of MSCTA for parasitic blood supply in hepatic carcinoma[J].journal interventional radiology,2008,(10):654.
[4]张茵,周兵,许秀芳,等.肝动脉化疗栓塞治疗原发性肝癌存活２０年一例[J].介入放射学杂志,2008,(09):684.
ZHANG Yin,ZHOU Bing,XU Xiufang,et al.Survival more than２０years after transarterial chemical embolization for hepatocellular carcinoma：A case report[J].journal interventional radiology,2008,(10):684.
[5]官泳松,贺庆.肝癌介入治疗中应用p５３的几个要点[J].介入放射学杂志,2008,(11):761.
GUAN Yongsong,HE Qing.Essentials in clinical application of p５３for tumors intervention－example of liver cancer[J].journal interventional radiology,2008,(10):761.
[6]肖运平,肖恩华.介入治疗在防治肝癌术后复发中的作用及进展[J].介入放射学杂志,2008,(11):831.
XIAO Yunping,XIAO Enhua.The role and progress of interventional therapy in the prevention and treatment of postoperative hepatocellular carcinoma recurrence[J].journal interventional radiology,2008,(10):831.
[7]史震山,陈自谦,杨熙章,等.原发性大肝癌患者TACE后S－腺苷蛋氨酸的护肝作用[J].介入放射学杂志,2008,(11):790.
SHI Zhenshan,CHEN Ziqian,YANG Xizhang,et al.The clinical study on the liver－protection of S－adenosy－methionine in large hepatocellular carcinoma patients after TACE[J].journal interventional radiology,2008,(10):790.
[8]王耀普,杨康健,赵思源,等.兔肝癌模型的改良接种及其DSA影像分析[J].介入放射学杂志,2010,(03):214.
WANG Yaopu,YANG Kangjian,ZHAO Siyuan,et al.The modified inoculation method for the preparation of rabbit VX２hepatic carcinoma model and DSA imagining observation[J].journal interventional radiology,2010,(10):214.
[9]贺洪德,贺晶,罗中华,等.肝动脉化疗栓塞联合门静脉栓塞治疗中晚期肝癌的疗效评价[J].介入放射学杂志,2010,(03):191.
HE Hongde,HE Jing,LUO Zhonghua,et al.Evaluation of the therapeutic effect of hepatic arterial chemoembolization combined with portal chemoembolization for advanced hepatic carcinomas[J].journal interventional radiology,2010,(10):191.
[10]李广琪,曹玮,李超,等.肝动脉热灌注对兔肝VX２肿瘤及正常肝组织血管渗透性功能的作用[J].介入放射学杂志,2010,(03):217.
LI Guangqi,CAO Wei,LI Chao,et al.Influence of hepatic artery thermotherapy on the vascular permeability of hepatic tumor tissue and normal liver tissue in VX２tumor－bearing rabbits[J].journal interventional radiology,2010,(10):217.